The DCIS #2 ROI contained many more invasive cells than the DCIS #1 ROI, and also less KRT15+ myoepithelial cells, suggesting that DCIS #2 ROI is more invasive than DCIS #1 ROI. Here, KRT15 is linked to ductal breast carcinoma in situ.